1
|
Labarrere CA, Kassab GS. Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Front Immunol 2021; 12:652252. [PMID: 34630377 PMCID: PMC8494786 DOI: 10.3389/fimmu.2021.652252] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 08/31/2021] [Indexed: 01/08/2023] Open
Abstract
The rapid outbreak of COVID-19 caused by the novel coronavirus SARS-CoV-2 in Wuhan, China, has become a worldwide pandemic affecting almost 204 million people and causing more than 4.3 million deaths as of August 11 2021. This pandemic has placed a substantial burden on the global healthcare system and the global economy. Availability of novel prophylactic and therapeutic approaches are crucially needed to prevent development of severe disease leading to major complications both acutely and chronically. The success in fighting this virus results from three main achievements: (a) Direct killing of the SARS-CoV-2 virus; (b) Development of a specific vaccine, and (c) Enhancement of the host's immune system. A fundamental necessity to win the battle against the virus involves a better understanding of the host's innate and adaptive immune response to the virus. Although the role of the adaptive immune response is directly involved in the generation of a vaccine, the role of innate immunity on RNA viruses in general, and coronaviruses in particular, is mostly unknown. In this review, we will consider the structure of RNA viruses, mainly coronaviruses, and their capacity to affect the lungs and the cardiovascular system. We will also consider the effects of the pattern recognition protein (PRP) trident composed by (a) Surfactant proteins A and D, mannose-binding lectin (MBL) and complement component 1q (C1q), (b) C-reactive protein, and (c) Innate and adaptive IgM antibodies, upon clearance of viral particles and apoptotic cells in lungs and atherosclerotic lesions. We emphasize on the role of pattern recognition protein immune therapies as a combination treatment to prevent development of severe respiratory syndrome and to reduce pulmonary and cardiovascular complications in patients with SARS-CoV-2 and summarize the need of a combined therapeutic approach that takes into account all aspects of immunity against SARS-CoV-2 virus and COVID-19 disease to allow mankind to beat this pandemic killer.
Collapse
Affiliation(s)
| | - Ghassan S Kassab
- California Medical Innovations Institute, San Diego, CA, United States
| |
Collapse
|
2
|
Komalla V, Allam VSRR, Kwok PCL, Sheikholeslami B, Owen L, Jaffe A, Waters SA, Mohammad S, Oliver BG, Chen H, Haghi M. A phospholipid-based formulation for the treatment of airway inflammation in chronic respiratory diseases. Eur J Pharm Biopharm 2020; 157:47-58. [PMID: 33065219 DOI: 10.1016/j.ejpb.2020.09.017] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 09/06/2020] [Accepted: 09/26/2020] [Indexed: 12/20/2022]
Abstract
Inflammation, the major hallmark of all chronic respiratory diseases is generally managed by inhaled corticosteroids. However, long term high dose treatment can result in significant side effects. Hence, there is a medical need for non-steroidal anti-inflammatory therapies to address airway inflammation. Phospholipids have been shown to reduce inflammation in several inflammatory conditions; however, their clinical translation has been limited to liposomal formulations traditionally used as drug carriers and their biological activity has not been investigated. Here we report the first application of empty liposomes as an anti-inflammatory treatment in airway inflammation. In the current study, liposomes (UTS-001) were prepared from cholesterol and a synthetic phospholipid (DOPC). The formulation was characterised in terms of size, charge, polydispersity index, morphology and stability as colloidal suspension and freeze-dried nanoparticles. Time-dependant uptake of UTS-001 in airway epithelial cells was observed which was inhibited by nystatin demonstrating that the uptake is via the caveolae pathway. In-vitro, in primary nasal epithelial cells, UTS-001 treatment successfully attenuated IL-6 levels following TNF-α stimulation. Consistent with the in-vitro findings, in-vivo, in the ovalbumin model of allergic airway inflammation, UTS-001 significantly reduced total immune cell counts in bronchoalveolar lavage fluid and reduced airway hyperresponsiveness in response to increasing doses of methacholine challenge. Therefore, our results establish UTS-001 as a potential anti-inflammatory treatment that may be useful as a therapeutic for lung inflammatory diseases.
Collapse
Affiliation(s)
- Varsha Komalla
- Graduate School of Health, University of Technology Sydney, Chippendale, NSW 2008, Australia; Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW 2037, Australia
| | - Venkata Sita Rama Raju Allam
- Graduate School of Health, University of Technology Sydney, Chippendale, NSW 2008, Australia; Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW 2037, Australia
| | - Philip Chi Lip Kwok
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
| | - Behjat Sheikholeslami
- Graduate School of Health, University of Technology Sydney, Chippendale, NSW 2008, Australia
| | - Louisa Owen
- School of Women's and Children's Health, Faculty of Medicine, The University of New South Wales, Kensington, NSW 2052, Australia; Molecular and Integrative Cystic Fibrosis Research Centre (miCF_RC), School of Medical Sciences, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
| | - Adam Jaffe
- School of Women's and Children's Health, Faculty of Medicine, The University of New South Wales, Kensington, NSW 2052, Australia; Molecular and Integrative Cystic Fibrosis Research Centre (miCF_RC), School of Medical Sciences, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
| | - Shafagh A Waters
- School of Women's and Children's Health, Faculty of Medicine, The University of New South Wales, Kensington, NSW 2052, Australia; Molecular and Integrative Cystic Fibrosis Research Centre (miCF_RC), School of Medical Sciences, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
| | - Shiva Mohammad
- School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Brian Gregory Oliver
- Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW 2037, Australia; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Hui Chen
- School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Mehra Haghi
- Graduate School of Health, University of Technology Sydney, Chippendale, NSW 2008, Australia.
| |
Collapse
|